# De novo protein design Proteins specified on a computer and realized in a lab — backbone geometry, binding interfaces and self-assembly designed from physical principles rather than found in nature. The table carries two institutions with fully sourced dossier ledgers; the field's well-funded companies are named in the note, not padded into the table. Source: https://en.bioecon.ru/technology/de-novo-protein-design/ Updated: 2026-09-18 ## Overview and value chain Markers: [EC: EU ATMP Regulation (EC) No 1394/2007 + FDA/NMPA biologics pathways for designed proteins | OECD: Biotechnology and health | Regulator: FDA (USA), EMA (EU), NMPA (China)] De novo protein design inverts the relationship between biology and engineering that held for the whole molecular age: instead of finding a protein that does something and improving it, the designer specifies the function — bind this target, catalyze that reaction, self-assemble into this cage — and computes a sequence that folds into a structure performing it. The discipline stands on a physical claim proven repeatedly since its founding demonstrations: that the mapping from amino-acid sequence to folded structure is computable, so a backbone never seen in nature can be specified, produced by solid-phase or recombinant synthesis, and verified against its design model by X-ray crystallography or cryo-EM. The Institute for Protein Design at the University of Washington — the field's center of gravity under David Baker — runs this loop as an institution: a $33 million annual research budget, a $7 million grant from the Washington Research Foundation in 2026, core laboratories spanning protein production, peptide synthesis, electron and light microscopy and X-ray crystallography, more than 250 members, 50-plus scientific publications per year and over 100 patents issued. The applied output is already a product class — designed vaccines, binders and self-assembling nanomaterials — and the discipline's industrialization runs through synthetic-biology manufacturing on the other side of the Pacific: Tianjin University's School of Synthetic Biology and Biomanufacturing, home to the State Key Laboratory of Synthetic Biology, ranks first globally in synthetic-biology research papers in Scopus and trains roughly 2,000 postgraduates. Key directions of de novo protein design: 1. **Computational backbone and interface design (Design-Build-Test):** specified geometry computed from physical principles, synthesized, and verified against the design model by crystallography or cryo-EM — the core loop the Institute for Protein Design runs across 50-plus publications a year on a $33 million annual budget. 2. **Designed vaccines and therapeutics (Function by Specification):** immunogens, binders and therapeutic candidates designed rather than discovered, moving through the ATMP and biologics frameworks that the FDA, EMA and NMPA operate. 3. **Self-assembling nanomaterials (Protein Architectures):** designed cages, lattices and arrays whose assembly is programmed by the sequence itself — the materials wing of the discipline. 4. **Genome-scale synthesis as the manufacturing arm (Synthetic Biology Institutes):** the design-build-test loop at chromosome and genome scale — Tianjin University's yeast genome synthesis work anchors the synthesis-and-assembly layer that turns designs into buildable biology. ### Sectoral value chain ``` [function specification] ──> [computational design] ──> [gene synthesis, expression] │ (structure-function verification) │ ▼ [product, material, therapy] <── [scale-up biomanufacturing] <── [designed protein validated] ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **Function specification** | binding, catalysis or assembly target | **In:** therapeutic or material need. **Out:** design brief. | | **Computational design** | backbone, interface and sequence computation | **In:** design brief, structure models. **Out:** designed amino-acid sequences. | | **Synthesis and expression** | gene synthesis and recombinant production | **In:** designed sequences. **Out:** designed proteins in the lab. | | **Verification** | structure and function against the model | **In:** designed proteins. **Out:** crystallography/cryo-EM-verified designs. | | **Iterative optimization** | design cycles folding experiment back into model | **In:** verification data. **Out:** improved design generations. | | **Biomanufacturing** | scale-up to product volumes | **In:** verified designs. **Out:** therapies, vaccines, materials at scale. | Cross-cutting technologies of the sector: - **Structure prediction networks (Computed Folds):** the models that made backbone computation tractable, now the substrate design iterates on. - **Gene synthesis and DNA fabrication (Build Layer):** the industrial synthesis that turns sequences into expressible constructs at design-loop speed. - **Cryo-EM and high-throughput characterization (Test Layer):** the verification instruments that close the design loop. --- ## US The US hosts the field's institutional center of gravity and its venture layer; the design loop's published output and patent estate are American in majority. ### The Baker-lab institute, patent estate, designed therapeutics pipeline - **Institute for Protein Design (University of Washington):** housed within the School of Medicine, directed by David Baker, with 250+ members, a $33 million annual research budget and a $7 million Washington Research Foundation grant in 2026, core R&D labs for protein production, peptide synthesis, electron and light microscopy and X-ray crystallography, 50-plus publications per year and 100-plus patents issued. - **Design of vaccine and therapeutic candidates:** the institute's research focus spans de novo protein design, computational biomolecular design, vaccine and therapeutic development and self-assembling systems — the pipeline venture companies license from. - **FDA pathway for designed biologics:** designed protein therapeutics file as biologics under FDA review — the regulatory classification that turns a computed sequence into a licensable product. --- ## CN China industrializes the synthesis-and-build arm of the discipline at university-institute scale, with Tianjin University the anchor institution by publication volume and training throughput. ### Tianjin University's synthetic biology complex, genome synthesis, talent throughput - **School of Synthetic Biology and Biomanufacturing (Tianjin University):** home to the State Key Laboratory of Synthetic Biology, the Frontier Science Center for Synthetic Biology and the Key Laboratory of Systems Bioengineering — a stack of national facilities dedicated to the build side of the design loop. - **Genome-scale synthesis:** research spanning yeast genome synthesis, DNA information storage and artificial cell construction — the chromosome-scale end of the build layer that makes designed genomes constructible. - **Publication and talent throughput:** first globally in synthetic-biology research papers in Scopus, with 20 senior national-level leading talents, 37 national-level young talents and roughly 2,000 postgraduates trained as of 2022 — the workforce the design discipline scales through. --- ## EU Europe contributes the ATMP regulatory framework that designed-protein therapeutics file under and a growing computational-design academic layer. ### ATMP framework for designed proteins, European design groups, regulator readiness - **EMA's ATMP framework (Regulation EC No 1394/2007):** designed-protein therapeutics and vaccines file under the advanced-therapy regime the EU pioneered — the classification that gives the field's outputs a European regulatory route. - **Academic design groups across member states:** European structural-biology and computational-design groups feed the field's method base, with cryo-EM facilities among the strongest verification infrastructures anywhere. - **Regulator readiness as a field asset:** a mature ATMP pathway means a designed therapeutic has a defined route to European patients — the institutional half of translation that pure software fields lack. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **Institute for Protein Design** | 🇺🇸 USA | *Design-build-test of novel proteins* | David Baker-directed; $33 m/yr budget + $7 m WRF grant (2026); 250+ members; 50+ papers/yr; 100+ patents | Unknown | | **Tianjin University** | 🇨🇳 China | *Synthetic biology school and State Key Lab* | Yeast genome synthesis; No. 1 globally in Scopus synthetic-biology papers; ~2,000 postgraduates trained; national facility stack | Research | --- ## Tech stack and innovations The stack is a loop — specify, compute, build, verify — and its innovations are the instruments that shortened the loop from years to weeks. 1. **Computational structure and interface design (Specify-to-Sequence):** - backbone geometry and binding interfaces are computed from physical principles; the output is an amino-acid sequence that has never existed. - case: the Institute for Protein Design's design-build-test loop — 50-plus publications per year, 100-plus patents issued, self-assembling systems among its research focuses. 2. **Gene synthesis and genome-scale construction (Build at Scale):** - designed sequences become expressible constructs through commercial and institute gene synthesis; at chromosome scale, whole genomes are synthesized and assembled. - case: Tianjin University's yeast genome synthesis program inside the State Key Laboratory of Synthetic Biology. 3. **High-throughput structural verification (Close the Loop):** - cryo-EM and X-ray crystallography verify designed structures against their models — the step that keeps design honest. - case: the institute's core labs span protein production, peptide synthesis, electron and light microscopy and X-ray crystallography in one facility stack. --- ## Value chains and production pipelines ### Industrial pipeline of a designed protein campaign (design-build-test-verify regime) ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. Function │ ───> │ 2. Computational │ │ specification │ │ design │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. Structural │ <─── │ 3. Gene synthesis and │ │ verification │ │ expression │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. Iterative │ ───> │ 6. Scale-up │ │ optimization │ │ biomanufacturing │ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: Function specification The need — bind a target, catalyze a reaction, assemble into a cage — is written as a design brief with quantitative acceptance criteria. #### Stage 2: Computational design Backbone geometry, interfaces and sequences are computed; the Institute for Protein Design's pipeline is the reference implementation of this stage as an institutional process. #### Stage 3: Gene synthesis and expression Designed sequences are synthesized to order and expressed recombinantly — Tianjin University's national facility stack is the industrial form of this stage at genome scale. #### Stage 4: Structural verification Expressed proteins are verified against design models by cryo-EM or X-ray crystallography — the institute's core labs keep verification inside the design loop rather than after it. #### Stage 5: Iterative optimization Verification data feeds the next design generation — the cycle that turns single successful designs into designable families. #### Stage 6: Scale-up biomanufacturing Verified designs move to recombinant production and, for therapeutics, through the FDA, EMA ATMP or NMPA frameworks that turn a computed sequence into a licensed product.